Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
Jörge E. Cortes(Augusta University Health), Meir Wetzler, Mark Goodman(University of Miami), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), John F. DiPersio(Washington University in St. Louis), Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Hugo F. Fernández(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Edward D. Ball(Sheba Medical Center), Maria R. Baer(University of Maryland, Baltimore)
Cited by 37
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k